If I indicated what you're suggesting, I might have misspoken. What I meant to say was not that we would adopt any kind of blanket rule about excluding these, but instead, in the case of orphan drugs, or drugs that target rare diseases, the evidence base is that much more limited at the time of approval by Health Canada. Ongoing monitoring to decide whether to pay for them and then continuously after that is that much more important. It's not that we would adopt any kind of blanket rule about in or out because they treat rare diseases, but rather the ongoing evidence collection is an imperative.
On May 30th, 2016. See this statement in context.